NASDAQ:QDEL - Quidel Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $69.81 -0.50 (-0.71 %) (As of 07/19/2018 04:00 PM ET)Previous Close$70.31Today's Range$69.70 - $70.6952-Week Range$31.01 - $71.22Volume128,800 shsAverage Volume338,787 shsMarket Capitalization$2.66 billionP/E Ratio-996.86Dividend YieldN/ABeta0.94 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California. Receive QDEL News and Ratings via Email Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical SymbolNASDAQ:QDEL CUSIP74838J10 Webwww.quidel.com Phone858-552-1100 Debt Debt-to-Equity Ratio0.40 Current Ratio1.36 Quick Ratio1.06 Price-To-Earnings Trailing P/E Ratio-996.86 Forward P/E Ratio30.35 P/E Growth1.23 Sales & Book Value Annual Sales$277.74 million Price / Sales9.42 Cash Flow$1.0715 per share Price / Cash65.15 Book Value$6.68 per share Price / Book10.45 Profitability EPS (Most Recent Fiscal Year)($0.07) Net Income$-8,160,000.00 Net Margins3.08% Return on Equity12.54% Return on Assets4.75% Miscellaneous Employees1,193 Outstanding Shares37,460,000Market Cap$2,657.54 Quidel (NASDAQ:QDEL) Frequently Asked Questions What is Quidel's stock symbol? Quidel trades on the NASDAQ under the ticker symbol "QDEL." How were Quidel's earnings last quarter? Quidel Co. (NASDAQ:QDEL) released its quarterly earnings data on Tuesday, May, 8th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.01 by $0.28. The business earned $169.10 million during the quarter, compared to analysts' expectations of $151.50 million. Quidel had a return on equity of 12.54% and a net margin of 3.08%. The business's quarterly revenue was up 129.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 EPS. View Quidel's Earnings History. When is Quidel's next earnings date? Quidel is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Quidel. What price target have analysts set for QDEL? 8 equities research analysts have issued twelve-month target prices for Quidel's shares. Their predictions range from $47.00 to $65.00. On average, they expect Quidel's share price to reach $58.8333 in the next twelve months. This suggests that the stock has a possible downside of 15.7%. View Analyst Ratings for Quidel. What is the consensus analysts' recommendation for Quidel? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 6 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Quidel's key competitors? Some companies that are related to Quidel include Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC) and Akers Biosciences (AKER). Who are Quidel's key executives? Quidel's management team includes the folowing people: Mr. Douglas C. Bryant, Pres, CEO & Director (Age 60)Mr. Randall J. Steward, Chief Financial Officer (Age 64)Mr. Robert J. Bujarski, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 50)Dr. Werner Kroll, Sr. VP of R&D (Age 61)Mr. Edward Keith Russell, Sr. VP of North America Operations (Age 50) Has Quidel been receiving favorable news coverage? Headlines about QDEL stock have trended somewhat negative this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Quidel earned a media sentiment score of -0.03 on Accern's scale. They also gave news headlines about the company an impact score of 46.91 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Who are Quidel's major shareholders? Quidel's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fred Alger Management Inc. (3.09%), Essex Investment Management Co. LLC (0.09%), Amalgamated Bank (0.01%), Campbell & CO Investment Adviser LLC (0.01%) and Winslow Evans & Crocker Inc. (0.01%). Company insiders that own Quidel stock include Douglas C Bryant, Edward Keith Russell, Jack W Schuler, John Tamerius, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Institutional Ownership Trends for Quidel. Which major investors are selling Quidel stock? QDEL stock was sold by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. Company insiders that have sold Quidel company stock in the last year include Douglas C Bryant, Edward Keith Russell, Jack W Schuler, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Insider Buying and Selling for Quidel. Which major investors are buying Quidel stock? QDEL stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Essex Investment Management Co. LLC, Amalgamated Bank and Winslow Evans & Crocker Inc.. View Insider Buying and Selling for Quidel. How do I buy shares of Quidel? Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quidel's stock price today? One share of QDEL stock can currently be purchased for approximately $69.81. How big of a company is Quidel? Quidel has a market capitalization of $2.66 billion and generates $277.74 million in revenue each year. The company earns $-8,160,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Quidel employs 1,193 workers across the globe. How can I contact Quidel? Quidel's mailing address is 12544 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-552-1100 or via email at [email protected] MarketBeat Community Rating for Quidel (NASDAQ QDEL)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 251 (Vote Outperform)Underperform Votes: 223 (Vote Underperform)Total Votes: 474MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote "Outperform" if you believe QDEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?